Opening book details…
About this nonfiction
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial by Motzer, Robert J (author);Powles, Thomas (author);Burotto, Mauricio (author);Escudier, Bernard (author);Bourlon, Maria T (author);Shah, Amishi Y (author);Suárez, Cristina (author);Hamzaj, Alketa (author);Porta, Camillo (author);Hocking, Christopher M (author);Kessler, Elizabeth R (author);Gurney, Howard (author);Tomita, Yoshihiko (author);Bedke, Jens (author);Zhang, Joshua (author);Simsek, Burcin (author);Scheffold, Christian (author);Apolo, Andrea B (author);Choueiri, Toni K (author) is a nonfiction available to read on EtoBox.
It is typically read by self-directed learners exploring a subject in depth.
Common subject areas: history, science, philosophy, social sciences.
- Author
- Motzer, Robert J (author);Powles, Thomas (author);Burotto, Mauricio (author);Escudier, Bernard (author);Bourlon, Maria T (author);Shah, Amishi Y (author);Suárez, Cristina (author);Hamzaj, Alketa (author);Porta, Camillo (author);Hocking, Christopher M (author);Kessler, Elizabeth R (author);Gurney, Howard (author);Tomita, Yoshihiko (author);Bedke, Jens (author);Zhang, Joshua (author);Simsek, Burcin (author);Scheffold, Christian (author);Apolo, Andrea B (author);Choueiri, Toni K (author)
- Publisher
- Elsevier BV
- Published
- 2022
- Language
- EN
- Category
- nonfiction
More by Motzer, Robert J (author);Powles, Thomas (author);Burotto, Mauricio (author);Escudier, Bernard (author);Bourlon, Maria T (author);Shah, Amishi Y (author);Suárez, Cristina (author);Hamzaj, Alketa (author);Porta, Camillo (author);Hocking, Christopher M (author);Kessler, Elizabeth R (author);Gurney, Howard (author);Tomita, Yoshihiko (author);Bedke, Jens (author);Zhang, Joshua (author);Simsek, Burcin (author);Scheffold, Christian (author);Apolo, Andrea B (author);Choueiri, Toni K (author)
Similar books
- Nivolumab Plus Ipilimumab Versus Nivolumab in Microsatellite Instability-high Metastatic Colorectal Cancer (CheckMate 8HW): a Randomised, Open-label, Phase 3 Trial — Prof Thierry André MD & Elena Elez MD & Heinz-Josef Lenz MD & Lars Henrik Jensen MD & Prof Yann Touchefeu MD & Eric Van Cutsem MD & Rocio Garcia-Carbonero MD & David Tougeron MD & Guillermo Ariel Mendez MD & Michael Schenker MD & Christelle de la... (2025)
- Nivolumab Plus Ipilimumab Versus Lenvatinib or Sorafenib as First-line Treatment for Unresectable Hepatocellular Carcinoma (CheckMate 9DW): an Open-label, Randomised, Phase 3 Trial — Thomas Yau MD & Prof Peter R Galle MD & Thomas Decaens MD & Prof Bruno Sangro MD & Shukui Qin MD & Leonardo G da Fonseca MD & Hatim Karachiwala MD & Prof Jean-Frederic Blanc MD & Prof Joong-Won Park MD & Prof Edward Gane MD & Matthias Pinter MD & Ana... (2025)
- Renal Cell Carcinoma : Clinical Management — Frédéric D. Birkhäuser MD, Nils Kroeger MD, Allan J. Pantuck MD, MS, FACS (auth.), Steven C. Campbell, Brian I. Rini (2013)
- Cabozantinib and Nivolumab with or Without Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma: a Randomized Phase 1 Trial — Hedyeh Ebrahimi & Nazli Dizman & Luis Meza & Jasnoor Malhotra & Xiaochen Li & Tanya Dorff & Paul Frankel & Marian Llamas-Quitiquit & Joann Hsu & Zeynep B. Zengin & Marice Alcantara & Daniela Castro & Benjamin Mercier & Neal Chawla & Alex... (2024)
- Adjuvant Nivolumab in Resected Stage IIB/C Melanoma: Primary Results from the Randomized, Phase 3 CheckMate 76K Trial — John M. Kirkwood & Michele Vecchio & Jeffrey Weber & Christoph Hoeller & Jean-Jacques Grob & Peter Mohr & Carmen Loquai & Caroline Dutriaux & Vanna Chiarion-Sileni & Jacek Mackiewicz & Piotr Rutkowski & Petr Arenberger & Gaelle Quereux & Tarek M.... (2024)
- Renal Cell Carcinoma of Variant Histology — Msaouel, Pavlos; Genovese, Giannicola; Tannir, Nizar M. (2023)